In summary, based on these findings, we can conclude that neither genetic xCT deficiency nor pharmacological xCT inhibition adversely affects the physiological adaptive immune response. The gene discussed is SLC7A11; the disease is hyperinsulinemic hypoglycemia, familial, 4.